References
- Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. 2012. The PATH (prospective antifungal therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 73:293–300. doi:https://doi.org/10.1016/j.diagmicrobio.2012.06.012
- Berkow EL, Lockhart SR. 2017. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 10:237–245. doi:https://doi.org/10.2147/IDR.S118892
- Calderone RA, Fonzi WA. 2001. Virulence factors of Candida albicans. Trends Microbiol. 9:327–335. doi:https://doi.org/10.1016/s0966-842x(01)02094-7
- Cha R, Sobel JD. 2004. Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther. 2:357–366. doi:https://doi.org/10.1586/14787210.2.3.357
- Chen CJ, Li QQ, Ma YN, Wang W, Cheng YX, Xu FR, Dong X. 2019. Antifungal effect of essential oils from five kinds of rutaceae plants - avoiding pesticide residue and resistance. Chem Biodivers. 16:e1800688 doi:https://doi.org/10.1002/cbdv.201800688
- Chen B, Ning M, Yang G. 2012. Effect of paeonol on antioxidant and immune regulatory activity in hepatocellular carcinoma rats. Molecules. 17:4672–4683. doi:https://doi.org/10.3390/molecules17044672
- Choy KW, Lau YS, Murugan D, Vanhoutte PM, Mustafa MR. 2018. Paeonol attenuates LPS-induced endothelial dysfunction and apoptosis by inhibiting BMP4 and TLR4 signaling simultaneously but independently. J Pharmacol Exp Ther. 364:420–432. doi:https://doi.org/10.1124/jpet.117.245217
- Clinical and Laboratory Standards Institute 2017. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard-third edition. CLSI document M60. Wayne, PA: Clinical and Laboratory Standards Institute.
- Fanning S, Mitchell AP. 2012. Fungal biofilms. PLoS Pathog. 8:e1002585. doi:https://doi.org/10.1371/journal.ppat.1002585
- Ge Y, Pan M, Zhang C, Wang C, Ma K, Yan G, Wang T, Wu D, Shao J. 2020. Paeonol alleviates dextran sodium sulfate induced colitis involving Candida albicans-associated dysbiosis. Med Mycol. 59:335–344. doi:https://doi.org/10.1093/mmy/myaa053
- Geary N. 2013. Understanding synergy. Am J Physiol Endocrinol Metab. 304:E237–53. doi:https://doi.org/10.1152/ajpendo.00308.2012
- Gow NAR, Yadav B. 2017. Microbe profile: Candida albicans: a shape-changing, opportunistic pathogenic fungus of humans. Microbiology (Reading). 163:1145–1147. doi:https://doi.org/10.1099/mic.0.000499
- Gu W, Guo D, Zhang L, Xu D, Sun S. 2016. The synergistic effect of azoles and fluoxetine against resistant Candida albicans strains is attributed to attenuating fungal virulence. Antimicrob Agents Chemother. 60:6179–6188. doi:https://doi.org/10.1128/AAC.03046-15
- Guirao-Abad JP, Sánchez-Fresneda R, Machado F, Argüelles JC, Martínez-Esparza M. 2018. Micafungin enhances the human macrophage response to Candida albicans through β-glucan exposure. Antimicrob Agents Chemother. 62:e02161–17. doi:https://doi.org/10.1128/AAC.02161-17
- Jafri H, Ahmad I. 2020. Thymus vulgaris essential oil and thymol inhibit biofilms and interact synergistically with antifungal drugs against drug resistant strains of Candida albicans and Candida tropicalis. J Mycol Med. 30:100911. doi:https://doi.org/10.1016/j.mycmed.2019.100911
- Jiao J, Sun L, Guo Z, Hou S, Holyst R, Lu Y, Feng X. 2016. Antibacterial and anticancer PDMS surface for mammalian cell growth using the Chinese herb extract paeonol(4-methoxy-2-hydroxyacetophenone). Sci Rep. 6:38973. doi:https://doi.org/10.1038/srep38973
- Khan A, Ahmad A, Xess I, Khan LA, Manzoor N. 2014. Ocimum sanctum essential oil inhibits virulence attributes in Candida albicans. Phytomedicine. 21:448–452. doi:https://doi.org/10.1016/j.phymed.2013.10.028
- Krezdorn J, Adams S, Coote PJ. 2014. A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa. J Med Microbiol. 63:945–955. doi:https://doi.org/10.1099/jmm.0.074245-0.
- Kwadha CA, Ong'amo GO, Ndegwa PN, Raina SK, Fombong AT. 2017. The biology and control of the Greater Wax Moth, Galleria mellonella. Insects. 8:61. doi:https://doi.org/10.3390/insects8020061
- Lemke A, Kiderlen AF, Kayser O. 2005. Amphotericin B. Appl Microbiol Biotechnol. 68:151–162. doi:https://doi.org/10.1007/s00253-005-1955-9
- Li J, Li Y, Pan S, Zhang L, He L, Niu Y. 2019. Paeonol attenuates ligation-induced periodontitis in rats by inhibiting osteoclastogenesis via regulating Nrf2/NF-κB/NFATc1 signaling pathway. Biochimie. 156:129–137. doi:https://doi.org/10.1016/j.biochi.2018.09.004
- Li Q, Liu J, Shao J, Da W, Shi G, Wang T, Wu D, Wang C. 2019. Decreasing cell population of individual candida species does not impair the virulence of Candida albicans and Candida glabrata mixed biofilms. Front Microbiol. 10:1600. doi:https://doi.org/10.3389/fmicb.2019.01600
- Li WR, Shi QS, Dai HQ, Liang Q, Xie XB, Huang XM, Zhao GZ, Zhang LX. 2016. Antifungal activity, kinetics and molecular mechanism of action of garlic oil against Candida albicans. Sci Rep. 6:22805 doi:https://doi.org/10.1038/srep22805
- Li Y, Yang J, Li X, Su S, Chen X, Sun S, Li Y. 2020. The effect of ginkgolide B combined with fluconazole against drug-resistant Candida albicans based on common resistance mechanisms. Int J Antimicrob Agents. 56:106030. doi:https://doi.org/10.1016/j.ijantimicag.2020.106030
- Liu J, Li Q, Wang C, Shao J, Wang T, Wu D, Ma K, Yan G, Yin D. 2020. Antifungal evaluation of traditional herbal monomers and their potential for inducing cell wall remodeling in Candida albicans and Candida auris. Biofouling. 36:319–331. doi:https://doi.org/10.1080/08927014.2020.1759559
- Liu Y, Ren H, Wang D, Zhang M, Sun S, Zhao Y. 2020. The synergistic antifungal effects of gypenosides combined with fluconazole against resistant Candida albicans via inhibiting the drug efflux and biofilm formation. Biomed Pharmacother. 130:110580. doi:https://doi.org/10.1016/j.biopha.2020.110580
- Lu M, Yang X, Yu C, Gong Y, Yuan L, Hao L, Sun S. 2018. Linezolid in combination with azoles induced synergistic effects against Candida albicans and protected Galleria mellonella against experimental candidiasis. Front Microbiol. 9:3142. doi:https://doi.org/10.3389/fmicb.2018.03142
- Mayer FL, Wilson D, Hube B. 2013. Candida albicans pathogenicity mechanisms. Virulence. 4:119–128. doi:https://doi.org/10.4161/viru.22913
- Mukherjee PK, Chandra J. 2004. Candida biofilm resistance. Drug Resist Updat. 7:301–309. doi:https://doi.org/10.1016/j.drup.2004.09.002
- Naglik JR, Fostira F, Ruprai J, Staab JF, Challacombe SJ, Sundstrom P. 2006. Candida albicans HWP1 gene expression and host antibody responses in colonization and disease. J Med Microbiol. 55:1323–1327. doi:https://doi.org/10.1099/jmm.0.46737-0
- Noble SM, Gianetti BA, Witchley JN. 2017. Candida albicans cell-type switching and functional plasticity in the mammalian host. Nat Rev Microbiol. 15:96–108. doi:https://doi.org/10.1038/nrmicro.2016.157
- Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 52:1 doi:https://doi.org/10.1093/jac/dkg301
- Papandreou V, Magiatis P, Chinou I, Kalpoutzakis E, Skaltsounis AL, Tsarbopoulos A. 2002. Volatiles with antimicrobial activity from the roots of Greek Paeonia taxa. J Ethnopharmacol. 81:101–104. doi:https://doi.org/10.1016/s0378-8741(02)00056-9
- Pereira R, Dos Santos Fontenelle RO, de Brito EHS, de Morais SM. 2021. Biofilm of Candida albicans: formation, regulation and resistance. J Appl Microbiol. 131:11–22. doi:https://doi.org/10.1111/jam.14949
- Price MF, Wilkinson ID, Gentry LO. 1982. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia. 20:7–14. doi:https://doi.org/10.1080/00362178285380031
- Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 45:2475–2479. doi:https://doi.org/10.1128/AAC.45.9.2475-2479.
- Schaller M, Borelli C, Korting HC, Hube B. 2005. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses. 48:365–377. doi:https://doi.org/10.1111/j.1439-0507.2005.01165.x
- Scorzoni L, de Lucas MP, Mesa-Arango AC, Fusco-Almeida AM, Lozano E, Cuenca-Estrella M, Mendes-Giannini MJ, Zaragoza O. 2013. Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile. PLoS One. 8:e60047 doi:https://doi.org/10.1371/journal.pone.0060047
- Sharma Y, Rastogi SK, Perwez A, Rizvi MA, Manzoor N. 2020. β-citronellol alters cell surface properties of Candida albicans to influence pathogenicity related traits. Med Mycol. 58:93–106. doi:https://doi.org/10.1093/mmy/myz009
- Shiradhone AB, Ingle SS, Zore AGB. 2018. Microenvironment responsive modulations in the fatty acid content, cell surface hydrophobicity, and adhesion of Candida albicans cells. J Fungi (Basel). 4:47. doi:https://doi.org/10.3390/jof4020047
- Sokolovská I, Rozenberg R, Riez C, Rouxhet PG, Agathos SN, Wattiau P. 2003. Carbon source-induced modifications in the mycolic acid content and cell wall permeability of Rhodococcus erythropolis E1. Appl Environ Microbiol. 69:7019–7027. doi: https://doi.org/10.1128/aem.69.12.7019-7027.
- Srivastava V, Singla RK, Dubey AK. 2018. Inhibition of biofilm and virulence factors of Candida albicans by partially purified secondary metabolites of Streptomyces chrestomyceticus Strain ADP4. Curr Top Med Chem. 18:925–945. doi:https://doi.org/10.2174/1568026618666180711154110
- Sudbery PE. 2011. Growth of Candida albicans hyphae. Nat Rev Microbiol. 9:737–748. doi:https://doi.org/10.1038/nrmicro2636
- Tsai CJ, Loh JM, Proft T. 2016. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence. 7:214–229. doi:https://doi.org/10.1080/21505594.2015.1135289
- Uwamahoro N, Verma-Gaur J, Shen HH, Qu Y, Lewis R, Lu J, Bambery K, Masters SL, Vince JE, Naderer T, et al. 2014. The pathogen Candida albicans hijacks pyroptosis for escape from macrophages. mBio. 5:e00003–e14. doi:https://doi.org/10.1128/mBio.00003-14
- Wagner H, Ulrich-Merzenich G. 2009. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 16:97–110. doi:https://doi.org/10.1016/j.phymed.2008.12.018
- Walker LA, Munro CA. 2020. Caspofungin induced cell wall changes of Candida species influences macrophage interactions. Front Cell Infect Microbiol. 10:164 doi:https://doi.org/10.3389/fcimb.2020.00164
- Wang D, Du Y, Xu H, Pan H, Wang R. 2019. Paeonol protects mitochondrial injury and prevents pulmonary vascular remodeling in hypoxia. Respir Physiol Neurobiol. 268:103252 doi:https://doi.org/10.1016/j.resp.2019.103252
- Wang Y, Lu C, Zhao X, Wang D, Liu Y, Sun S. 2021. Antifungal activity and potential mechanism of Asiatic acid alone and in combination with fluconazole against Candida albicans. Biomed Pharmacother. 139:111568 doi:https://doi.org/10.1016/j.biopha.2021.111568
- Wang T, Shao J, Da W, Li Q, Shi G, Wu D, Wang C. 2018. Strong synergism of palmatine and fluconazole/itraconazole against planktonic and biofilm cells of Candida species and efflux-associated antifungal mechanism. Front Microbiol. 9:2892. doi:https://doi.org/10.3389/fmicb.2018.02892
- Wang J, Wu G, Chu H, Wu Z, Sun J. 2020. Paeonol derivatives and pharmacological activities: a review of recent progress. Mini Rev Med Chem. 20:466–482. doi:https://doi.org/10.2174/1389557519666191015204223
- Wang Q, Xu X, Kang Z, Zhang Z, Li Y. 2019. Paeonol prevents IL-1β-induced inflammatory response and degradation of type II collagen in human primary chondrocytes. Artif Cells Nanomed Biotechnol. 47:2139–2145. doi:https://doi.org/10.1080/21691401.
- Wang F, Zhu M, Jiang N, Zhang M, Feng L, Jia X. 2019. Paeonol ameliorates lipopolysaccharides-induced acute lung injury by regulating TLR4/MyD88/ NF-κB signaling pathway. Pharmazie. 74:101–106. doi:https://doi.org/10.1691/ph.2019.8860
- Wiederhold NP. 2017. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 10:249–259. doi:https://doi.org/10.2147/IDR.S124918
- Wu J, Wu D, Ma K, Wang T, Shi G, Shao J, Wang C, Yan G. 2020a. Paeonol ameliorates murine alcohol liver disease via mycobiota-mediated Dectin-1/IL-1β signaling pathway. J Leukoc Biol. 108:199–214. doi:https://doi.org/10.1002/JLB.3MA0120-325RR
- Wu X, Wu G, Zhang W, Gu G, Sha S, Wang X. 2003. Experiment on extraction, sulfonate of paeonol and its antibiotic effect on plant pathogen. Zhong Yao Cai. 26:778–780.
- Wu J, Wu D, Zhao Y, Si Y, Mei L, Shao J, Wang T, Yan G, Wang C. 2020b. Sodium new houttuyfonate inhibits Candida albicans biofilm formation by inhibiting the Ras1-cAMP-Efg1 pathway revealed by RNA-seq. Front Microbiol. 11:2075. doi:https://doi.org/10.3389/fmicb.2020.02075.
- Wubulikasimu A, Huang Y, Wali A, Yili A, Rong M. 2020. A designed antifungal peptide with therapeutic potential for clinical drug-resistant Candida albicans. Biochem Biophys Res Commun. 533:404–409. doi:https://doi.org/10.1016/j.bbrc.2020.08.117
- Wuyts J, Van Dijck P, Holtappels M. 2018. Fungal persister cells: the basis for recalcitrant infections? PLoS Pathog. 14:e1007301 doi:https://doi.org/10.1371/journal.ppat.1007301
- Yin J, Wu N, Zeng F, Cheng C, Kang K, Yang H. 2013. Paeonol induces apoptosis in human ovarian cancer cells. Acta Histochem. 115:835–839. doi:https://doi.org/10.1016/j.acthis.2013.04.004
- Zarnowski R, Sanchez H, Covelli AS, Dominguez E, Jaromin A, Bernhardt J, Mitchell KF, Heiss C, Azadi P, Mitchell A, et al. 2018. Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis. PLoS Biol. 16:e2006872 doi:https://doi.org/10.1371/journal.pbio.2006872
- Zhang L, Li DC, Liu LF. 2019. Paeonol: pharmacological effects and mechanisms of action. Int Immunopharmacol. 72:413–421. doi:https://doi.org/10.1016/j.intimp.2019.04.033